Economist: Governments Negotiate Drug Prices "With Their Eyes Closed"

The current system for negotiating medication prices, particularly for high-cost, life-saving drugs, is fundamentally flawed, according to economist Sabine Vogler. In an interview with DER STANDARD, Vogler asserts that governments are essentially negotiating blind, lacking the crucial information needed to secure fair prices from pharmaceutical giants. This opacity benefits drug manufacturers while severely undermining the bargaining power of public health systems, which are tasked with providing care to their citizens.

Vogler's research highlights the immense financial strain imposed by innovative treatments, exemplified by cancer drugs like Keytruda. While these medications represent medical miracles, revolutionizing therapies and offering new hope, they simultaneously represent an economic nightmare for public coffers. The high expenditure associated with these drugs, as previously reported by DER STANDARD in collaboration with an international research consortium, places an unsustainable burden on healthcare budgets.

From an Austrian perspective, this issue is critical. Our public health system strives for universal access to care, but escalating drug prices threaten this principle. The lack of transparency in pharmaceutical pricing not only impacts national budgets but also raises questions about equity and access. DER STANDARD believes that shedding light on these negotiations is essential for ensuring the long-term sustainability and fairness of our healthcare system. We must empower public institutions with the knowledge they need to negotiate effectively, ensuring that groundbreaking medical advancements are accessible to all who need them, not just those who can afford the exorbitant price tag.

“

Staaten verhandeln über Medikamentepreise mit verbundenen Augen